Business Context and Reporting Period
Company: Viking Therapeutics, Inc. (Nasdaq: VKTX)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2025
Business Overview: Viking is a clinical-stage biopharmaceutical company developing novel therapies for metabolic and endocrine disorders. Key programs include VK2735 (GLP-1/GIP dual agonist for obesity and type 2 diabetes), VK2809 (TRβ agonist for NASH/MASH), and VK0214 (TRβ agonist for X-ALD). The company has no product revenue and relies on cash reserves and financing activities.
Key Financial Metrics
| Metric (in thousands) | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 |
|---|---|---|
| Revenues | $0 | $0 |
| Net Loss | $(111,190) | $(49,606) |
| Loss Per Share (Basic & Diluted) | $(0.99) | $(0.46) |
| Research & Development Expenses | $101,543 | $47,872 |
| General & Administrative Expenses | $28,500 | $20,255 |
| Interest Income, Net | $18,897 | $18,565 |
| Cash Used in Operating Activities | $(99,392) | $(34,647) |
| Cash Provided by Investing Activities | $105,751 | $(585,851) |
| Cash Provided by Financing Activities | $856 | $608,942 |
| Cash, Cash Equivalents & Short-Term Investments (June 30, 2025) | $807,724 | $902,612 (Dec 31, 2024) |
Material Changes vs. Prior Period
- Increased Operating Loss: Net loss for the six months ended June 30, 2025, more than doubled to $111.2 million from $49.6 million in the prior year period, driven primarily by a 112% increase in R&D expenses.
- R&D Expense Surge: R&D expenses rose to $101.5 million (from $47.9 million) due to the initiation of the Phase 3 VANQUISH program for VK2735, increased clinical study costs ($27.2M increase), and manufacturing costs ($21.1M increase).
- G&A Expense Growth: General and administrative expenses increased 40.7% to $28.5 million, largely due to higher stock-based compensation ($6.4M increase) and legal/patent services.
- Investing Cash Flow Shift: Unlike the prior year which saw significant net cash used in investing activities ($585.9M outflow), the current period generated $105.8 million in net cash from investing activities due to proceeds from investment maturities ($461.8M) exceeding purchases ($356.1M).
- Financing Activity Decline: Financing cash flow dropped significantly to $0.9 million compared to $608.9 million in the prior year, as the company did not conduct major equity offerings in the current period (the March 2024 offering occurred in the prior year).
Guidance, Outlook, and Risks
- Clinical Pipeline Progress:
- VK2735: Initiated Phase 3 VANQUISH program (obesity and type 2 diabetes) in June 2025. Phase 2 VENTURE results are expected in the second half of 2025. Oral formulation Phase 2 results also expected in H2 2025.
- VK2809: Positive 52-week histologic data from VOYAGE study announced in June 2024.
- VK0214: Phase 1b results announced in October 2024 showed safety and reduction in VLCFA levels.
- Liquidity Outlook: Management believes cash, cash equivalents, and short-term investments of $807.7 million are sufficient to fund operations through at least September 30, 2026.
- Manufacturing Commitments: Entered into multi-year agreements with CordenPharma in March 2025 for dedicated API and fill/finish capacity for VK2735, requiring prepayments from 2025 to 2028.
- Stock Repurchase Program: Authorized a $250 million repurchase program in February 2025; no shares repurchased during the quarter ended June 30, 2025.
- Key Risks:
- Dependence on the success of a limited number of drug candidates (VK2735, VK2809, VK0214).
- Reliance on third-party manufacturers (CordenPharma) and licensors (Ligand Pharmaceuticals).
- Need for additional capital to fund future operations and commercialization efforts.
- Regulatory uncertainty and potential delays in clinical trials.
Investor Verification Checklist
- Cash Burn Rate: Verify the sustainability of the $99.4 million operating cash burn over the six-month period against the $807.7 million cash balance.
- Phase 3 Enrollment: Monitor enrollment progress and timelines for the newly initiated VANQUISH Phase 3 trials for VK2735.
- Manufacturing Prepayments: Review the impact of prepayments to CordenPharma on future cash flow and working capital.
- Stock-Based Compensation: Assess the impact of the $24.9 million stock-based compensation expense (6 months) on future dilution and expense recognition.
- Legal Proceedings: Track the status of the trade secret litigation against Ascletis Defendants, where the ITC recently affirmed determinations in Viking's favor.